{"gene":"P2RX7","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":2008,"finding":"P2X7 receptor C-terminal SH3 death domain interacts with Src tyrosine kinase, and this interaction mediates downstream Pannexin-1 (Panx1) activation. TAT-peptides spanning the P2X7R C-terminus competed with Src binding, reducing Panx1-dependent large-conductance currents and membrane permeabilization to dye. Src tyrosine phosphorylation following BzATP stimulation was blocked by KN-62, TAT-P2X7 peptide, and Src inhibitor PP2.","method":"Whole-cell patch-clamp electrophysiology, siRNA knockdown of Panx1, competition assay with membrane-permeant TAT-P2X7 peptides, pharmacological inhibition (KN-62, PP2, carbenoxolone, mefloquine), dye uptake permeabilization assay","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal functional assays (electrophysiology + permeabilization + competition peptide), single lab but multiple orthogonal methods","pmids":["18596211"],"is_preprint":false},{"year":2015,"finding":"P2X7 receptor directly interacts with NLRP3 inflammasome scaffold protein at discrete subplasmalemmal sites. ATP or BzATP stimulation caused localized cytoplasmic Ca2+ increases that drove P2X7R recruitment and a 4-fold increase in P2X7R/NLRP3 co-immunoprecipitation within 1–2 min. P2X7R down-modulation also caused 2–8-fold up-regulation of NLRP3 mRNA in microglial cells and primary macrophages from P2X7R-/- mice.","method":"Coimmunoprecipitation, confocal microscopy, RT-PCR, Western blot, calcium imaging, P2X7R-/- primary cells","journal":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP with confocal co-localization, genetic KO validation, multiple orthogonal methods in single study","pmids":["25690658"],"is_preprint":false},{"year":2020,"finding":"Paxillin acts as a molecular bridge between P2X7 receptor and NLRP3 inflammasome. Extracellular ATP induces paxillin phosphorylation and promotes formation of a P2X7R-Paxillin-NLRP3 ternary complex at the plasma membrane. Paxillin facilitates NLRP3 deubiquitination via USP13, and paxillin is required for ATP-induced NLRP3 inflammasome activation in mouse BMDMs, BMDCs, and human PBMCs/THP-1 macrophages.","method":"Co-immunoprecipitation, confocal microscopy showing membrane translocation, genetic knockdown/knockout, deubiquitination assay, USP13 identification, human primary cell functional assays","journal":"BMC biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP of ternary complex, deubiquitination biochemistry, validated in multiple cell types including primary human cells","pmids":["33243234"],"is_preprint":false},{"year":2015,"finding":"P2X7 receptor activation regulates rapid unconventional secretion of transglutaminase-2 (TG2). Extracellular ATP promotes TG2 secretion from macrophages via P2X7R; introduction of functional P2X7R into HEK293 cells is sufficient to confer TG2 export. TG2 release requires receptor membrane pore formation (not Ca2+ signaling alone or membrane depolarization), does not involve pannexin channels, and is pharmacologically separable from microvesicle shedding. A gain-of-function P2X7R mutation associated with autoimmune disease caused enhanced TG2 externalization correlating with increased pore activity.","method":"Pharmacological antagonism, heterologous expression in HEK293 cells, gain-of-function mutation analysis, separation of vesicle shedding from secretion by pharmacological agents, pore formation assay","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — reconstitution in HEK293 cells, multiple pharmacological dissections, gain-of-function mutation validation, multiple orthogonal readouts","pmids":["26542019"],"is_preprint":false},{"year":2017,"finding":"P2X4 and P2X7 receptor subunits can physically associate to form heterotrimeric channels, detected by FRET between fluorophore-labeled subunits in Xenopus oocytes. However, electrophysiological analysis of ATP-induced whole-cell currents, concentration-response curves, and effects of subtype-specific drugs (ivermectin, PSB-15417, oATP, A438079) were consistent with homomeric P2X4 and P2X7 channels coexisting, with no electrophysiologically distinct heteromeric phenotype.","method":"FRET between fluorophore-tagged subunits expressed in Xenopus oocytes, two-electrode voltage clamp electrophysiology, pharmacological dissection with subtype-selective agents","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — FRET physical interaction established, electrophysiology shows no distinct functional heteromer; single lab with two orthogonal methods","pmids":["29213241"],"is_preprint":false},{"year":2021,"finding":"P2X7 receptor localizes to mitochondria in fibroblasts, microglial cells, and heart tissue. Loss of P2X7R decreases basal respiratory rate, ATP-coupled respiration, maximal uncoupled respiration, resting mitochondrial potential, and mitochondrial matrix Ca2+ levels. P2X7R-null mice have larger hearts with smaller mitochondria, reduced stroke volume, ejection fraction, fractional shortening, and cardiac output, and severely reduced physical fitness.","method":"Subcellular fractionation and confocal localization to mitochondria, mitochondrial respirometry (Seahorse), mitochondrial Ca2+ measurement, cardiac ultrasound in P2rx7-/- mice, treadmill fitness testing","journal":"Function (Oxford, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct fractionation/imaging localization tied to functional consequence in multiple cell types and in vivo cardiac/metabolic phenotype in KO mice","pmids":["35330818"],"is_preprint":false},{"year":2000,"finding":"P2X7 receptor participates in multinucleated giant cell (MGC) formation. Blockade with a specific monoclonal antibody prevents macrophage fusion in vitro. P2X7-high expressing phagocytes fuse only with other P2X7-high cells. During MGC formation, caspase-3 is activated (a P2X7-stimulated enzyme), and P2X7R is preferentially localized at cell-to-cell contact sites.","method":"Monoclonal antibody blockade, cell selection for high/low P2X7 expression, caspase-3 activity assay, immunolocalization at cell contacts, ATP-degrading enzyme controls (apyrase/hexokinase)","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody blockade plus cell-selection epistasis plus localization study, single lab, multiple orthogonal methods","pmids":["10982408"],"is_preprint":false},{"year":2012,"finding":"P2X7 receptor expression promotes tumor growth in vivo. HEK293 cells expressing P2X7 showed increased tumorigenicity, proliferation, reduced apoptosis, elevated NFATc1 activation, enhanced vascular network, and elevated VEGF secretion compared to controls. Tumor growth and neoangiogenesis were blocked by intratumoral oxidized-ATP (P2X7 inhibitor), VEGF-blocking antibody bevacizumab, or P2X7 silencing in vivo.","method":"In vivo xenograft tumor model, intratumoral inhibitor injection, P2X7 silencing (siRNA in vivo), anti-VEGF antibody treatment, immunohistochemistry, VEGF measurement","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo gain-of-function and loss-of-function (inhibitor + silencing), mechanistic dissection via anti-VEGF intervention, multiple orthogonal readouts","pmids":["22505653"],"is_preprint":false},{"year":2018,"finding":"Tet1 and Tet2 methylcytosine dioxygenases maintain mesenchymal stem cell (MSC) homeostasis via demethylation of the P2rX7 promoter. Tet1/Tet2 double knockout reduces P2rX7 expression, decreasing exosome release and causing intracellular accumulation of miR-297a-5p, miR-297b-5p, and miR-297c-5p, which inhibit Runx2 signaling and impair BMMSC function. Overexpression of P2rX7 in Tet1/2 double KO mice rescues the impaired BMMSCs and osteoporotic phenotype.","method":"Genetic knockout (Tet1/Tet2 DKO mice), promoter methylation analysis, exosome quantification, miRNA profiling, Runx2 signaling assay, P2rX7 overexpression rescue experiment","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO phenotype rescued by specific overexpression, epigenetic mechanism (promoter demethylation) linked to downstream miRNA/Runx2 pathway, multiple orthogonal methods","pmids":["29858571"],"is_preprint":false},{"year":2018,"finding":"P2X7 receptor activation induces release of CD14 (a GPI-anchored LPS co-receptor) in extracellular vesicles from macrophages, resulting in net reduction of membrane CD14 and functionally attenuating LPS-induced (but not monophosphoryl lipid A-induced) pro-inflammatory cytokine production. In a murine sepsis model, P2X7 activity maintained elevated circulating CD14 levels; reduced P2X7 activity correlated with higher bacterial load, exacerbated organ damage, and premature death.","method":"Extracellular vesicle isolation, flow cytometry for CD14 membrane levels, LPS stimulation assay, P2X7-/- mice in a sepsis model, bacterial load measurement","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic in vitro dissection of vesicle-mediated CD14 shedding with functional consequence, validated in vivo with KO mice in sepsis model","pmids":["33135636"],"is_preprint":false},{"year":2020,"finding":"P2X7 stimulation of tumor-infiltrating effector CD8+ T cells induces cellular senescence via mitochondrial reactive oxygen species generation and p38 MAPK-dependent upregulation of Cdkn1a (p21Waf1/Cip1), impairing cell cycling. Adoptive transfer of P2rx7-/- tumor-specific CD8+ T cells significantly reduced tumor growth and extended survival compared to wild-type T cells in mice.","method":"Genetic KO (P2rx7-/-) adoptive T cell transfer, cell cycle analysis, mitochondrial ROS measurement, p38 MAPK inhibition, p21 upregulation assay, in vivo tumor growth measurement","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic KO adoptive transfer with mechanistic dissection of ROS/p38/p21 pathway, multiple orthogonal methods","pmids":["32699136"],"is_preprint":false},{"year":2018,"finding":"P2X7 receptor regulates astroglial autophagy (clasmatodendrosis) after status epilepticus through a MAPK1/2-SP1-HSPB1 signaling axis. Loss of P2rx7 leads to prolonged HSPB1 induction due to impaired MAPK1/2-mediated SP1 phosphorylation; upregulated HSPB1 then triggers ER stress and PRKAA1(AMPK1)/ULK1- and AKT1/GSK3B/SH3GLB1-mediated autophagic pathways independently of mTOR.","method":"P2rx7-/- mice, kainic acid-induced status epilepticus model, Western blot for pathway components, phosphorylation analysis of SP1 and MAPK1/2","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined signaling pathway dissection, single lab, in vivo/ex vivo evidence","pmids":["29749377"],"is_preprint":false},{"year":2019,"finding":"ATP-P2X7 receptor axis promotes UV-induced melanogenesis. Extracellular ATP released from UVB-irradiated keratinocytes activates P2X7R on melanocytes to promote melanin production via intracellular Ca2+ and PKC/CREB signaling. CRISPR/Cas9 P2X7 knockout melanocytes (MNT1) failed to upregulate MITF when co-cultured with UV-irradiated keratinocytes, confirming P2X7R is required for this paracrine signaling.","method":"P2X7R pharmacological blockade, CRISPR/Cas9 knockout of P2X7 in melanocytes, co-culture with UV-irradiated keratinocytes, MITF expression assay, melanin measurement, Ca2+ signaling and PKC/CREB pathway analysis","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR KO with co-culture model plus pharmacological blockade plus downstream signaling mechanistic dissection, multiple orthogonal methods","pmids":["30926287"],"is_preprint":false},{"year":2022,"finding":"Irradiation of glioblastoma (GBM) cells causes a dramatic isoform switch: P2X7A splice variant is down-regulated and P2X7B is up-regulated. P2X7B activation by extracellular ATP after irradiation generates a trophic/growth-promoting stimulus, as P2X7 blockers during post-irradiation recovery potentiated irradiation-dependent cytotoxicity.","method":"Isoform-specific RT-PCR/Western blot before and after irradiation, P2X7 pharmacological blockade post-irradiation, cell viability assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — isoform expression shift with pharmacological functional follow-up, single lab, two orthogonal methods","pmids":["35075119"],"is_preprint":false},{"year":2022,"finding":"P2X7 receptor deletion in mice suppresses gamma-radiation-induced hyposalivation. Irradiated P2X7R-/- mice maintained normal stimulated salivary flow rates, whereas wild-type irradiated mice showed significant decreases. P2X7R activation elevated PGE2 release from parotid cells following gamma-radiation, and pharmacological P2X7R antagonism (A438079) preserved salivary flow rates in wild-type mice.","method":"P2X7R-/- mouse model, gamma-irradiation, stimulated salivary flow rate measurement, PGE2 release assay from primary parotid cells, pharmacological antagonism (A438079), apoptosis assay","journal":"American journal of physiology. Regulatory, integrative and comparative physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with pharmacological confirmation and defined PGE2 mechanism, single lab","pmids":["30892913"],"is_preprint":false},{"year":2024,"finding":"microRNA-211-5p targets P2RX7 mRNA; downregulation of miR-211-5p in epilepsy causes P2RX7 upregulation. P2RX7 regulates GPX4/HO-1 by alleviating lipid peroxidation through suppression of MAPK/ERK signaling, contributing to neuronal ferroptosis. Genetic silencing of P2RX7 or induction of miR-211-5p significantly reduced seizure score and duration in murine models.","method":"Bioinformatics, epilepsy patient blood samples, mouse epilepsy models (PTZ and KA), miR-211-5p overexpression, P2RX7 genetic silencing, GPX4/HO-1/ERK pathway Western blot, seizure behavioral scoring","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic silencing with defined pathway readouts, confirmed in multiple models, single lab","pmids":["38191407"],"is_preprint":false},{"year":2022,"finding":"P2X7 receptor expression is required for glioma radiosensitivity. P2X7R silencing blocked gamma-radiation (2 Gy)-induced cytotoxicity in glioma cells in a time-dependent pore-activity-dependent manner (measured by ethidium bromide uptake). In vivo, P2X7R-silenced GL261-bearing mice failed to respond to radiotherapy (8 Gy), while wild-type P2X7R-expressing mice showed significant tumor volume reduction. ATP acted synergistically with radiotherapy to increase annexin V incorporation.","method":"P2X7R siRNA silencing, pharmacological antagonism, ethidium bromide pore uptake assay, annexin V apoptosis assay, in vivo GL261 tumor model with radiotherapy, tumor volume measurement","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo loss-of-function with defined mechanistic pore-activity readout, single lab","pmids":["26358881"],"is_preprint":false},{"year":2015,"finding":"Paroxetine inhibits human P2X7 receptor responses in a concentration-dependent manner (IC50 ~24 µM), reducing ATP-induced dye uptake and inward currents. Trifluoperazine also suppresses human P2X7 responses (IC50 ~6.4 µM). Neither drug inhibited rodent P2X7, and mutation of residue F95L did not alter the inhibitory effect of either drug, indicating they do not bind at this known site. Both drugs suppressed P2X7-induced IL-1β secretion from LPS-primed human CD14+ monocytes.","method":"Recombinant human P2X7 in HEK-293 cells, dye uptake assay, whole-cell patch clamp, site-directed mutagenesis (F95L), primary human monocyte IL-1β secretion assay, species comparison (human vs. rodent P2X7)","journal":"Purinergic signalling","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro electrophysiology and mutagenesis on recombinant receptor plus primary cell functional assay, single lab, multiple orthogonal methods","pmids":["26341077"],"is_preprint":false},{"year":2022,"finding":"P2X7 receptor activation by P2RX7 stimulation in glioblastoma cells promotes pore formation as measured by ethidium bromide uptake, and this activity is essential for radiation-induced cytotoxicity. Both P2X7A (full-length) and P2X7B (truncated C-terminus) isoforms are expressed in GBM, with distinct contributions to cell survival versus death responses.","method":"Isoform-specific expression analysis, ethidium bromide pore uptake assay, pharmacological blockade, irradiation experiments, cell viability","journal":"Cell death & disease","confidence":"Low","confidence_rationale":"Tier 3 / Weak — isoform-level pharmacological data, single lab, limited mechanistic resolution for isoform-specific function","pmids":["35075119"],"is_preprint":false}],"current_model":"P2X7R is a trimeric, ATP-gated non-selective cation channel whose long intracellular C-terminus orchestrates multiple downstream signaling events: it directly binds NLRP3 inflammasome scaffold protein at subplasmalemmal sites (driving localized Ca2+ increases that amplify their association), recruits paxillin as a molecular bridge to facilitate USP13-mediated NLRP3 deubiquitination and inflammasome activation, and its C-terminal SH3 death domain engages Src kinase to activate Pannexin-1 large-conductance currents; additionally, P2X7R localizes to mitochondria and is required for normal mitochondrial respiration and Ca2+ homeostasis, mediates unconventional TG2 secretion and vesicular CD14 release contingent on macropore formation, promotes tumor growth via NFATc1/VEGF signaling, and drives macrophage multinucleated giant cell formation through caspase-3 activation at cell-contact sites, with its expression regulated epigenetically via Tet1/Tet2-dependent demethylation of the P2rX7 promoter and post-transcriptionally by miR-211-5p."},"narrative":{"mechanistic_narrative":"P2RX7 (P2X7R) is an ATP-gated cation channel whose activation couples extracellular nucleotide sensing to membrane permeabilization and a broad program of inflammatory, metabolic, and proliferative signaling [PMID:25690658, PMID:26542019]. Its cytoplasmic C-terminus serves as a signaling hub: an SH3 death domain engages Src kinase to drive Pannexin-1 large-conductance currents and dye-permeable membrane permeabilization [PMID:18596211], and upon ATP/BzATP stimulation the receptor is recruited to subplasmalemmal sites where localized Ca2+ rises promote its direct association with the NLRP3 inflammasome scaffold [PMID:25690658]. Paxillin bridges P2X7R and NLRP3 into a ternary complex and enables USP13-mediated NLRP3 deubiquitination, a step required for ATP-induced inflammasome activation in macrophages, dendritic cells, and human monocytes [PMID:33243234]. Through macropore formation the receptor drives unconventional secretion of transglutaminase-2 and vesicular shedding of CD14, the latter dampening LPS responsiveness and limiting bacterial burden in sepsis [PMID:26542019, PMID:33135636]. P2X7R also localizes to mitochondria and is required for normal respiration, mitochondrial Ca2+ loading, and cardiac/physical fitness in vivo [PMID:35330818]. In the tumor context it promotes tumor growth via NFATc1-dependent VEGF secretion and neoangiogenesis [PMID:22505653], yet in tumor-infiltrating CD8+ T cells it imposes mitochondrial-ROS/p38/p21-dependent senescence that restrains anti-tumor immunity [PMID:32699136]. Receptor abundance is set epigenetically by Tet1/Tet2-dependent demethylation of the P2rX7 promoter, which controls exosome release and Runx2 signaling in mesenchymal stem cells [PMID:29858571], and post-transcriptionally by miR-211-5p [PMID:38191407]. P2X7R further mediates paracrine UV-induced melanogenesis [PMID:30926287], macrophage multinucleated giant cell formation [PMID:10982408], and modulates seizure, autophagy, and radiation-response phenotypes across neural and tumor tissues [PMID:29749377, PMID:38191407, PMID:26358881].","teleology":[{"year":2000,"claim":"Established that P2X7R is not merely a channel but a driver of macrophage fusion, linking receptor activity to multinucleated giant cell formation and a cell-death effector.","evidence":"Monoclonal antibody blockade, P2X7-high/low cell selection, caspase-3 activity assay, and immunolocalization at cell contacts","pmids":["10982408"],"confidence":"Medium","gaps":["Molecular fusion machinery downstream of P2X7R not identified","Direct caspase-3 substrate at contact sites unknown"]},{"year":2008,"claim":"Defined how the P2X7R C-terminus transduces signal beyond ion flux, showing its SH3 death domain recruits Src to activate Pannexin-1 and membrane permeabilization.","evidence":"Whole-cell patch-clamp, Panx1 siRNA, competing TAT-P2X7 C-terminal peptides, and pharmacological inhibition in a dye-uptake assay","pmids":["18596211"],"confidence":"Medium","gaps":["Direct structural basis of SH3-Src binding not resolved","Whether Src acts directly on Panx1 not established"]},{"year":2012,"claim":"Showed P2X7R expression is sufficient to promote tumor growth, connecting receptor activity to NFATc1-driven VEGF secretion and neoangiogenesis.","evidence":"HEK293 xenografts with in vivo P2X7 silencing, oxidized-ATP and anti-VEGF (bevacizumab) intervention, immunohistochemistry","pmids":["22505653"],"confidence":"High","gaps":["Link from P2X7R activation to NFATc1 activation not biochemically mapped","Endogenous tumor relevance vs. HEK overexpression"]},{"year":2015,"claim":"Identified the direct physical interaction between P2X7R and the NLRP3 scaffold, providing a spatial mechanism (subplasmalemmal Ca2+) for inflammasome assembly.","evidence":"Reciprocal Co-IP, confocal co-localization, calcium imaging, and P2X7R-/- primary cells with NLRP3 mRNA quantification","pmids":["25690658"],"confidence":"High","gaps":["Interaction interface residues not mapped","Mechanism of Ca2+-driven recruitment unresolved"]},{"year":2015,"claim":"Demonstrated that P2X7R macropore formation, not Ca2+ or depolarization alone, drives unconventional TG2 secretion, dissecting pore activity from other receptor outputs.","evidence":"Heterologous HEK293 reconstitution, pharmacological dissection separating secretion from vesicle shedding, gain-of-function disease-mutant analysis","pmids":["26542019"],"confidence":"High","gaps":["Molecular identity of the secretory route downstream of pore formation unknown","How TG2 accesses the pore not defined"]},{"year":2017,"claim":"Tested whether P2X4 and P2X7 form functional heteromers, finding physical association by FRET but no electrophysiologically distinct heteromeric channel.","evidence":"FRET between tagged subunits in Xenopus oocytes and two-electrode voltage clamp with subtype-selective pharmacology","pmids":["29213241"],"confidence":"Medium","gaps":["Physiological significance of P2X4-P2X7 association unclear","Heteromer behavior in native cells untested"]},{"year":2018,"claim":"Revealed epigenetic control of P2rX7 abundance, placing the receptor downstream of Tet1/Tet2 demethylation in mesenchymal stem cell and bone homeostasis.","evidence":"Tet1/Tet2 DKO mice, promoter methylation analysis, exosome/miRNA profiling, and P2rX7 overexpression rescue of osteoporotic phenotype","pmids":["29858571"],"confidence":"High","gaps":["How P2X7R activity controls exosome release mechanistically unclear","Direct miR-297/Runx2 link to receptor pore vs. signaling untested"]},{"year":2018,"claim":"Connected P2X7R to innate immune tuning by showing it sheds membrane CD14 in vesicles to attenuate LPS responses and limit bacterial load in sepsis.","evidence":"EV isolation, flow cytometry of membrane CD14, LPS stimulation, and P2X7-/- mouse sepsis model with bacterial load measurement","pmids":["33135636"],"confidence":"High","gaps":["Mechanism coupling pore formation to CD14 vesicle loading not defined","Whether shedding is direct or via downstream proteases unknown"]},{"year":2018,"claim":"Linked P2X7R loss to dysregulated astroglial autophagy, defining a MAPK1/2-SP1-HSPB1 signaling axis after status epilepticus.","evidence":"P2rx7-/- mice in kainic acid model with phosphorylation analysis of SP1 and MAPK1/2 and autophagy pathway Western blots","pmids":["29749377"],"confidence":"Medium","gaps":["Direct receptor-to-MAPK1/2 coupling not established","Single-lab in vivo correlative pathway data"]},{"year":2019,"claim":"Showed P2X7R mediates a paracrine keratinocyte-melanocyte signaling loop driving UV-induced melanogenesis via Ca2+/PKC/CREB and MITF.","evidence":"CRISPR/Cas9 P2X7 knockout melanocytes co-cultured with UV-irradiated keratinocytes, pharmacological blockade, MITF and melanin assays","pmids":["30926287"],"confidence":"High","gaps":["Direct CREB target genes downstream not mapped","Relevance to human pigmentation in vivo untested"]},{"year":2020,"claim":"Defined paxillin as the molecular bridge linking P2X7R to NLRP3, with USP13-mediated deubiquitination as a required activation step.","evidence":"Co-IP of P2X7R-Paxillin-NLRP3 ternary complex, deubiquitination assay identifying USP13, and functional validation in mouse and human primary cells","pmids":["33243234"],"confidence":"High","gaps":["How ATP triggers paxillin phosphorylation upstream unclear","Stoichiometry/order of ternary complex assembly unknown"]},{"year":2020,"claim":"Uncovered an immunosuppressive cell-intrinsic role: P2X7R drives senescence in tumor-infiltrating CD8+ T cells, identifying a target to enhance anti-tumor immunity.","evidence":"P2rx7-/- adoptive T cell transfer, mitochondrial ROS measurement, p38 MAPK inhibition, p21 upregulation, and in vivo tumor growth","pmids":["32699136"],"confidence":"High","gaps":["How receptor signaling generates mitochondrial ROS not resolved","Whether senescence is reversible by transient blockade untested"]},{"year":2021,"claim":"Established a non-canonical mitochondrial localization for P2X7R essential for respiration, mitochondrial Ca2+, and organismal cardiac and physical fitness.","evidence":"Subcellular fractionation/confocal localization, Seahorse respirometry, mitochondrial Ca2+ measurement, and cardiac ultrasound plus fitness testing in P2rx7-/- mice","pmids":["35330818"],"confidence":"High","gaps":["How P2X7R traffics to and functions within mitochondria unknown","Whether mitochondrial pool is channel-active not established"]},{"year":2022,"claim":"Showed P2X7R isoform balance shapes tumor radiation response, with irradiation switching from P2X7A to a growth-promoting P2X7B variant in glioblastoma.","evidence":"Isoform-specific RT-PCR/Western blot before and after irradiation with P2X7 blockade and viability assays","pmids":["35075119","35075119"],"confidence":"Medium","gaps":["Mechanism of the trophic P2X7B signal not defined","Low-resolution dissection of isoform-specific function"]},{"year":2022,"claim":"Demonstrated pore-activity-dependent P2X7R function is required for glioma radiosensitivity in vitro and in vivo, framing the receptor as a radiotherapy modifier.","evidence":"P2X7R siRNA silencing, ethidium bromide pore uptake, annexin V apoptosis, and in vivo GL261 radiotherapy model","pmids":["26358881"],"confidence":"Medium","gaps":["How pore activity links to radiation-induced death pathway unclear","Single-lab in vivo data"]},{"year":2022,"claim":"Showed P2X7R activation drives radiation-induced hyposalivation through PGE2 release, identifying a tissue-protection rationale for antagonism.","evidence":"P2X7R-/- mice, gamma-irradiation, salivary flow measurement, PGE2 assay from primary parotid cells, and A438079 antagonism","pmids":["30892913"],"confidence":"Medium","gaps":["Coupling of receptor activation to PGE2 synthesis not mapped","Cell type responsible within gland unresolved"]},{"year":2024,"claim":"Placed P2RX7 within a miR-211-5p-controlled circuit that drives neuronal ferroptosis via GPX4/HO-1 and MAPK/ERK in epilepsy.","evidence":"Patient blood samples, PTZ and KA mouse models, miR-211-5p overexpression, P2RX7 silencing, GPX4/HO-1/ERK Western blots, and seizure scoring","pmids":["38191407"],"confidence":"Medium","gaps":["Direct miR-211-5p binding to P2RX7 transcript needs confirmation","How receptor activity modulates ERK/GPX4 mechanistically unclear"]},{"year":2015,"claim":"Characterized species-specific pharmacological inhibitors of human P2X7R acting outside the known F95 site, with functional suppression of IL-1beta secretion.","evidence":"Recombinant human P2X7 in HEK-293, dye uptake, patch clamp, F95L mutagenesis, species comparison, and primary monocyte IL-1beta assay","pmids":["26341077"],"confidence":"Medium","gaps":["Actual binding site of paroxetine/trifluoperazine not identified","Whether inhibition is allosteric or competitive unresolved"]},{"year":null,"claim":"It remains unresolved how a single receptor coordinates its distinct outputs (channel, macropore, mitochondrial, scaffolding) at the structural and trafficking level, and whether these are spatially segregated receptor pools or sequential conformational states.","evidence":"No timeline discovery resolves the structural switch governing channel vs. macropore vs. mitochondrial functions.","pmids":[],"confidence":"Low","gaps":["No structural model connecting pore dilation to scaffolding functions","Mechanism of mitochondrial targeting unknown","Determinants of context-specific signaling output undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,12]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2]},{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[3,18]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,2,3]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,2,9]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,12]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[10,15,16]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[11]}],"complexes":["P2X7R-Paxillin-NLRP3 ternary complex","P2X4-P2X7 heterotrimer"],"partners":["NLRP3","PXN","USP13","SRC","PANX1","P2RX4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q99572","full_name":"P2X purinoceptor 7","aliases":["ATP receptor","P2Z receptor","Purinergic receptor"],"length_aa":595,"mass_kda":68.6,"function":"ATP-gated nonselective transmembrane cation channel that requires high millimolar concentrations of ATP for activation (PubMed:17483156, PubMed:25281740, PubMed:9038151). Upon ATP binding, it rapidly opens to allow the influx of small cations Na(+) and Ca(2+), and the K(+) efflux (PubMed:17483156, PubMed:20453110, PubMed:28235784, PubMed:39262850). Also has the ability to form a large pore in the cell membrane, allowing the passage of large cationic molecules (PubMed:17483156). In microglia, may mediate NADPH transport across the plasma membrane (PubMed:39142135). In immune cells, P2RX7 acts as a molecular sensor in pathological inflammatory states by detecting and responding to high local concentrations of extracellar ATP. In microglial cells, P2RX7 activation leads to the release of pro-inflammatory cytokines, such as IL-1beta and IL-18, through the activation of the NLRP3 inflammasome and caspase-1 (PubMed:26877061). Cooperates with KCNK6 to activate NLRP3 inflammasome (By similarity). Activates death pathways leading to apoptosis and autophagy (PubMed:21821797, PubMed:23303206, PubMed:28326637). Activates death pathways leading to pyroptosis (By similarity) Shows ion channel activity but no macropore function Non-functional channel Non-functional channel","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q99572/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/P2RX7","classification":"Not Classified","n_dependent_lines":17,"n_total_lines":1208,"dependency_fraction":0.014072847682119206},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/P2RX7","total_profiled":1310},"omim":[{"mim_id":"618334","title":"CYTOCHROME b(-254) CHAPERONE 1; CYBC1","url":"https://www.omim.org/entry/618334"},{"mim_id":"603939","title":"POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 6; KCNK6","url":"https://www.omim.org/entry/603939"},{"mim_id":"602566","title":"PURINERGIC RECEPTOR P2X, LIGAND-GATED ION CHANNEL, 7; P2RX7","url":"https://www.omim.org/entry/602566"},{"mim_id":"151400","title":"LEUKEMIA, CHRONIC LYMPHOCYTIC; CLL","url":"https://www.omim.org/entry/151400"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":16.8}],"url":"https://www.proteinatlas.org/search/P2RX7"},"hgnc":{"alias_symbol":["P2X7","MGC20089"],"prev_symbol":[]},"alphafold":{"accession":"Q99572","domains":[{"cath_id":"-","chopping":"20-50_333-384","consensus_level":"high","plddt":93.6777,"start":20,"end":384},{"cath_id":"2.60.490.10","chopping":"60-113_173-326","consensus_level":"high","plddt":90.7892,"start":60,"end":326},{"cath_id":"-","chopping":"123-170","consensus_level":"medium","plddt":90.9806,"start":123,"end":170},{"cath_id":"-","chopping":"400-445_466-581","consensus_level":"high","plddt":85.1427,"start":400,"end":581}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99572","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99572-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99572-F1-predicted_aligned_error_v6.png","plddt_mean":88.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=P2RX7","jax_strain_url":"https://www.jax.org/strain/search?query=P2RX7"},"sequence":{"accession":"Q99572","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99572.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99572/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99572"}},"corpus_meta":[{"pmid":"28723547","id":"PMC_28723547","title":"The P2X7 Receptor in Infection and Inflammation.","date":"2017","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/28723547","citation_count":1026,"is_preprint":false},{"pmid":"17692395","id":"PMC_17692395","title":"Liaisons dangereuses: P2X(7) and the inflammasome.","date":"2007","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17692395","citation_count":414,"is_preprint":false},{"pmid":"29467654","id":"PMC_29467654","title":"The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?","date":"2018","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29467654","citation_count":352,"is_preprint":false},{"pmid":"24928329","id":"PMC_24928329","title":"The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease.","date":"2014","source":"Pharmacological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/24928329","citation_count":344,"is_preprint":false},{"pmid":"29288626","id":"PMC_29288626","title":"The P2X7 receptor: A main player in inflammation.","date":"2017","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29288626","citation_count":331,"is_preprint":false},{"pmid":"22505653","id":"PMC_22505653","title":"Expression of P2X7 receptor increases in vivo tumor growth.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22505653","citation_count":319,"is_preprint":false},{"pmid":"18596211","id":"PMC_18596211","title":"P2X7 receptor-Pannexin1 complex: pharmacology and signaling.","date":"2008","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18596211","citation_count":294,"is_preprint":false},{"pmid":"29439897","id":"PMC_29439897","title":"The Elusive P2X7 Macropore.","date":"2018","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29439897","citation_count":230,"is_preprint":false},{"pmid":"22963440","id":"PMC_22963440","title":"P2X7 receptors: channels, pores and more.","date":"2012","source":"CNS & neurological disorders drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/22963440","citation_count":217,"is_preprint":false},{"pmid":"28676924","id":"PMC_28676924","title":"The P2X7 Receptor.","date":"2017","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/28676924","citation_count":202,"is_preprint":false},{"pmid":"25690658","id":"PMC_25690658","title":"The P2X7 receptor directly interacts with the NLRP3 inflammasome scaffold protein.","date":"2015","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/25690658","citation_count":194,"is_preprint":false},{"pmid":"31440138","id":"PMC_31440138","title":"P2X7 Interactions and Signaling - Making Head or Tail of It.","date":"2019","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31440138","citation_count":186,"is_preprint":false},{"pmid":"33359010","id":"PMC_33359010","title":"P2X7 receptor and the NLRP3 inflammasome: Partners in crime.","date":"2020","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33359010","citation_count":185,"is_preprint":false},{"pmid":"21988719","id":"PMC_21988719","title":"The human P2X7 receptor and its role in innate immunity.","date":"2011","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/21988719","citation_count":164,"is_preprint":false},{"pmid":"20599520","id":"PMC_20599520","title":"Microglia: proliferation and activation driven by the P2X7 receptor.","date":"2010","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20599520","citation_count":164,"is_preprint":false},{"pmid":"28360855","id":"PMC_28360855","title":"The P2X7 Receptor-Interleukin-1 Liaison.","date":"2017","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28360855","citation_count":146,"is_preprint":false},{"pmid":"28747388","id":"PMC_28747388","title":"Neuronal P2X7 Receptors Revisited: Do They Really Exist?","date":"2017","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28747388","citation_count":142,"is_preprint":false},{"pmid":"32581786","id":"PMC_32581786","title":"P2X7 in Cancer: From Molecular Mechanisms to Therapeutics.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32581786","citation_count":138,"is_preprint":false},{"pmid":"32848594","id":"PMC_32848594","title":"The P2X7 Receptor: Central Hub of Brain Diseases.","date":"2020","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32848594","citation_count":126,"is_preprint":false},{"pmid":"33328588","id":"PMC_33328588","title":"Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology.","date":"2020","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/33328588","citation_count":122,"is_preprint":false},{"pmid":"31174279","id":"PMC_31174279","title":"P2X7 Receptor Signaling in Stress and Depression.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31174279","citation_count":115,"is_preprint":false},{"pmid":"32166013","id":"PMC_32166013","title":"P2X7 receptor mediates NLRP3 inflammasome activation in depression and diabetes.","date":"2020","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/32166013","citation_count":114,"is_preprint":false},{"pmid":"21303345","id":"PMC_21303345","title":"Significance of P2X7 receptor variants to human health and disease.","date":"2011","source":"Recent patents on DNA & gene sequences","url":"https://pubmed.ncbi.nlm.nih.gov/21303345","citation_count":112,"is_preprint":false},{"pmid":"22102807","id":"PMC_22102807","title":"The role of the P2X₇ receptor in infectious diseases.","date":"2011","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/22102807","citation_count":112,"is_preprint":false},{"pmid":"32825423","id":"PMC_32825423","title":"P2X7 Receptors Amplify CNS Damage in Neurodegenerative Diseases.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32825423","citation_count":106,"is_preprint":false},{"pmid":"29858571","id":"PMC_29858571","title":"Tet1 and Tet2 maintain mesenchymal stem cell homeostasis via demethylation of the P2rX7 promoter.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29858571","citation_count":99,"is_preprint":false},{"pmid":"26042119","id":"PMC_26042119","title":"P2X7 on Mouse T Cells: One Channel, Many Functions.","date":"2015","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26042119","citation_count":99,"is_preprint":false},{"pmid":"27038372","id":"PMC_27038372","title":"P2X7 Receptor as a Therapeutic Target.","date":"2016","source":"Advances in protein chemistry and structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/27038372","citation_count":94,"is_preprint":false},{"pmid":"27724045","id":"PMC_27724045","title":"P2X7 receptor antagonists: a patent review (2010-2015).","date":"2016","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/27724045","citation_count":84,"is_preprint":false},{"pmid":"27513892","id":"PMC_27513892","title":"Targeting of the P2X7 receptor in pancreatic cancer and stellate cells.","date":"2016","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27513892","citation_count":80,"is_preprint":false},{"pmid":"30093269","id":"PMC_30093269","title":"P2X7 Receptor: A Potential Therapeutic Target for Depression?","date":"2018","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30093269","citation_count":78,"is_preprint":false},{"pmid":"18410246","id":"PMC_18410246","title":"The P2X7 receptor as a therapeutic target.","date":"2008","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/18410246","citation_count":77,"is_preprint":false},{"pmid":"33243234","id":"PMC_33243234","title":"Paxillin mediates ATP-induced activation of P2X7 receptor and NLRP3 inflammasome.","date":"2020","source":"BMC biology","url":"https://pubmed.ncbi.nlm.nih.gov/33243234","citation_count":75,"is_preprint":false},{"pmid":"30003075","id":"PMC_30003075","title":"P2RX7 Purinoceptor as a Therapeutic Target-The Second Coming?","date":"2018","source":"Frontiers in chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30003075","citation_count":74,"is_preprint":false},{"pmid":"28479300","id":"PMC_28479300","title":"P2X7 receptor antagonism: Implications in diabetic retinopathy.","date":"2017","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28479300","citation_count":72,"is_preprint":false},{"pmid":"29213241","id":"PMC_29213241","title":"Interaction of Purinergic P2X4 and P2X7 Receptor Subunits.","date":"2017","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29213241","citation_count":70,"is_preprint":false},{"pmid":"15579103","id":"PMC_15579103","title":"Agonists and antagonists acting at P2X7 receptor.","date":"2004","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15579103","citation_count":69,"is_preprint":false},{"pmid":"25310682","id":"PMC_25310682","title":"P2X7 receptor modulates inflammatory and functional pulmonary changes induced by silica.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25310682","citation_count":61,"is_preprint":false},{"pmid":"24247209","id":"PMC_24247209","title":"P2X7 blockade attenuates mouse liver fibrosis.","date":"2013","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/24247209","citation_count":61,"is_preprint":false},{"pmid":"25591582","id":"PMC_25591582","title":"P2X7 receptors: role in bone cell formation and function.","date":"2015","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25591582","citation_count":59,"is_preprint":false},{"pmid":"30098011","id":"PMC_30098011","title":"P2X7 as a scavenger receptor for innate phagocytosis in the brain.","date":"2018","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30098011","citation_count":59,"is_preprint":false},{"pmid":"30593878","id":"PMC_30593878","title":"Regulation of P2X7 receptor expression and function in the brain.","date":"2018","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/30593878","citation_count":58,"is_preprint":false},{"pmid":"32581707","id":"PMC_32581707","title":"The Role of P2X7 Receptor in Alzheimer's Disease.","date":"2020","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32581707","citation_count":58,"is_preprint":false},{"pmid":"34122013","id":"PMC_34122013","title":"Role of P2X7 Receptors in Immune Responses During Neurodegeneration.","date":"2021","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34122013","citation_count":57,"is_preprint":false},{"pmid":"21619470","id":"PMC_21619470","title":"P2X7 receptor antagonism in the treatment of cancers.","date":"2011","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/21619470","citation_count":56,"is_preprint":false},{"pmid":"31778766","id":"PMC_31778766","title":"The role and pharmacological properties of the P2X7 receptor in neuropathic pain.","date":"2019","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/31778766","citation_count":52,"is_preprint":false},{"pmid":"35075119","id":"PMC_35075119","title":"Irradiation causes senescence, ATP release, and P2X7 receptor isoform switch in glioblastoma.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35075119","citation_count":52,"is_preprint":false},{"pmid":"32699136","id":"PMC_32699136","title":"P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors.","date":"2020","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32699136","citation_count":52,"is_preprint":false},{"pmid":"30921559","id":"PMC_30921559","title":"Role of the P2X7 receptor in tumor-associated inflammation.","date":"2019","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30921559","citation_count":51,"is_preprint":false},{"pmid":"10982408","id":"PMC_10982408","title":"P2X(7) receptor and polykarion formation.","date":"2000","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/10982408","citation_count":51,"is_preprint":false},{"pmid":"32004973","id":"PMC_32004973","title":"Effect of P2X7 receptor on tumorigenesis and its pharmacological properties.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32004973","citation_count":50,"is_preprint":false},{"pmid":"34799827","id":"PMC_34799827","title":"Involvement of P2X7 receptors in chronic pain disorders.","date":"2021","source":"Purinergic signalling","url":"https://pubmed.ncbi.nlm.nih.gov/34799827","citation_count":50,"is_preprint":false},{"pmid":"35330818","id":"PMC_35330818","title":"Mitochondrial P2X7 Receptor Localization Modulates Energy Metabolism Enhancing Physical Performance.","date":"2021","source":"Function (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/35330818","citation_count":48,"is_preprint":false},{"pmid":"23602648","id":"PMC_23602648","title":"Associations between depression severity and purinergic receptor P2RX7 gene polymorphisms.","date":"2013","source":"Journal of affective disorders","url":"https://pubmed.ncbi.nlm.nih.gov/23602648","citation_count":48,"is_preprint":false},{"pmid":"33168313","id":"PMC_33168313","title":"The effect of P2X7 on cadmium-induced osteoporosis in mice.","date":"2020","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/33168313","citation_count":48,"is_preprint":false},{"pmid":"33477845","id":"PMC_33477845","title":"P2X7 Variants in Oncogenesis.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33477845","citation_count":47,"is_preprint":false},{"pmid":"29749377","id":"PMC_29749377","title":"P2RX7-MAPK1/2-SP1 axis inhibits MTOR independent HSPB1-mediated astroglial autophagy.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29749377","citation_count":47,"is_preprint":false},{"pmid":"33995071","id":"PMC_33995071","title":"P2X7 Receptor-Mediated Inflammation in Cardiovascular Disease.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33995071","citation_count":45,"is_preprint":false},{"pmid":"29122639","id":"PMC_29122639","title":"The P2RX7 polymorphism rs2230912 is associated with depression: A meta-analysis.","date":"2017","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/29122639","citation_count":45,"is_preprint":false},{"pmid":"32668623","id":"PMC_32668623","title":"P2X7 Receptor at the Crossroads of T Cell Fate.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32668623","citation_count":44,"is_preprint":false},{"pmid":"26358881","id":"PMC_26358881","title":"P2X7 receptor as predictor gene for glioma radiosensitivity and median survival.","date":"2015","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26358881","citation_count":43,"is_preprint":false},{"pmid":"32587592","id":"PMC_32587592","title":"The P2X7 Receptor as Regulator of T Cell Development and Function.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32587592","citation_count":42,"is_preprint":false},{"pmid":"24533115","id":"PMC_24533115","title":"Lack of association of P2RX7 gene rs2230912 polymorphism with mood disorders: a meta-analysis.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24533115","citation_count":41,"is_preprint":false},{"pmid":"35850190","id":"PMC_35850190","title":"P2X7 receptor in inflammation and pain.","date":"2022","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/35850190","citation_count":40,"is_preprint":false},{"pmid":"29470314","id":"PMC_29470314","title":"Genetic variation in P2RX7 and pain tolerance.","date":"2018","source":"Pain","url":"https://pubmed.ncbi.nlm.nih.gov/29470314","citation_count":40,"is_preprint":false},{"pmid":"26542019","id":"PMC_26542019","title":"P2X7 receptor activation regulates rapid unconventional export of transglutaminase-2.","date":"2015","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/26542019","citation_count":40,"is_preprint":false},{"pmid":"17584060","id":"PMC_17584060","title":"Molecular probes for P2X7 receptor studies.","date":"2007","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17584060","citation_count":39,"is_preprint":false},{"pmid":"31551714","id":"PMC_31551714","title":"Pleiotropic Roles of P2X7 in the Central Nervous System.","date":"2019","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31551714","citation_count":39,"is_preprint":false},{"pmid":"38191407","id":"PMC_38191407","title":"The microRNA-211-5p/P2RX7/ERK/GPX4 axis regulates epilepsy-associated neuronal ferroptosis and oxidative stress.","date":"2024","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/38191407","citation_count":38,"is_preprint":false},{"pmid":"33135636","id":"PMC_33135636","title":"CD14 release induced by P2X7 receptor restricts inflammation and increases survival during sepsis.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/33135636","citation_count":38,"is_preprint":false},{"pmid":"30834550","id":"PMC_30834550","title":"P2X7 receptor in cardiovascular disease: The heart side.","date":"2019","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30834550","citation_count":37,"is_preprint":false},{"pmid":"30986625","id":"PMC_30986625","title":"Novel biologics targeting the P2X7 ion channel.","date":"2019","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30986625","citation_count":37,"is_preprint":false},{"pmid":"31015145","id":"PMC_31015145","title":"Targeting P2X4 and P2X7 receptors in multiple sclerosis.","date":"2019","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31015145","citation_count":37,"is_preprint":false},{"pmid":"31466708","id":"PMC_31466708","title":"Alternative splicing of P2RX7 pre-messenger RNA in health and diseases: Myth or reality?","date":"2019","source":"Biomedical journal","url":"https://pubmed.ncbi.nlm.nih.gov/31466708","citation_count":35,"is_preprint":false},{"pmid":"34239877","id":"PMC_34239877","title":"The P2X7 Receptor in Tumor Immunity.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34239877","citation_count":34,"is_preprint":false},{"pmid":"33644066","id":"PMC_33644066","title":"The P2X7 Receptor in Osteoarthritis.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33644066","citation_count":33,"is_preprint":false},{"pmid":"36508838","id":"PMC_36508838","title":"Aluminum induces neuroinflammation via P2X7 receptor activating NLRP3 inflammasome pathway.","date":"2022","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/36508838","citation_count":33,"is_preprint":false},{"pmid":"33122998","id":"PMC_33122998","title":"P2X7 Receptor Upregulation in Huntington's Disease Brains.","date":"2020","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33122998","citation_count":33,"is_preprint":false},{"pmid":"35682841","id":"PMC_35682841","title":"Gallic Acid Alleviates Visceral Pain and Depression via Inhibition of P2X7 Receptor.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35682841","citation_count":33,"is_preprint":false},{"pmid":"30664971","id":"PMC_30664971","title":"Association of purinergic receptor P2RX7 gene polymorphisms with depression symptoms.","date":"2019","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/30664971","citation_count":31,"is_preprint":false},{"pmid":"38370420","id":"PMC_38370420","title":"Role and therapeutic targets of P2X7 receptors in neurodegenerative diseases.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38370420","citation_count":30,"is_preprint":false},{"pmid":"30892913","id":"PMC_30892913","title":"P2X7 receptor deletion suppresses γ-radiation-induced hyposalivation.","date":"2019","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30892913","citation_count":29,"is_preprint":false},{"pmid":"35588154","id":"PMC_35588154","title":"P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy.","date":"2022","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/35588154","citation_count":29,"is_preprint":false},{"pmid":"29601335","id":"PMC_29601335","title":"Mechanosensitive Ion Channels: TRPV4 and P2X7 in Disseminating Cancer Cells.","date":"2018","source":"Cancer journal (Sudbury, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/29601335","citation_count":29,"is_preprint":false},{"pmid":"20846359","id":"PMC_20846359","title":"Metaanalysis of P2X7 gene polymorphisms and tuberculosis susceptibility.","date":"2010","source":"FEMS immunology and medical microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/20846359","citation_count":28,"is_preprint":false},{"pmid":"36376084","id":"PMC_36376084","title":"P2X7 Receptor and Purinergic Signaling: Orchestrating Mitochondrial Dysfunction in Neurodegenerative Diseases.","date":"2022","source":"eNeuro","url":"https://pubmed.ncbi.nlm.nih.gov/36376084","citation_count":28,"is_preprint":false},{"pmid":"31031209","id":"PMC_31031209","title":"The role of microglia and P2X7 receptors in gliomas.","date":"2019","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/31031209","citation_count":27,"is_preprint":false},{"pmid":"30737253","id":"PMC_30737253","title":"A Mechanism-Based Approach to P2X7 Receptor Action.","date":"2019","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30737253","citation_count":27,"is_preprint":false},{"pmid":"35134386","id":"PMC_35134386","title":"The P2X7 receptor as a new pharmacological target for retinal diseases.","date":"2022","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35134386","citation_count":27,"is_preprint":false},{"pmid":"30954685","id":"PMC_30954685","title":"Targeting P2X7 receptors as a means for treating retinal disease.","date":"2019","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/30954685","citation_count":27,"is_preprint":false},{"pmid":"30901737","id":"PMC_30901737","title":"Immunomodulatory effects of P2X7 receptor in intracellular parasite infections.","date":"2019","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30901737","citation_count":26,"is_preprint":false},{"pmid":"31169175","id":"PMC_31169175","title":"P2X7 receptor signaling during adult hippocampal neurogenesis.","date":"2019","source":"Neural regeneration research","url":"https://pubmed.ncbi.nlm.nih.gov/31169175","citation_count":26,"is_preprint":false},{"pmid":"24163006","id":"PMC_24163006","title":"Natural compounds with P2X7 receptor-modulating properties.","date":"2013","source":"Purinergic signalling","url":"https://pubmed.ncbi.nlm.nih.gov/24163006","citation_count":25,"is_preprint":false},{"pmid":"30901735","id":"PMC_30901735","title":"P2X7 purinoceptor as a therapeutic target in muscular dystrophies.","date":"2019","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30901735","citation_count":24,"is_preprint":false},{"pmid":"26341077","id":"PMC_26341077","title":"Paroxetine suppresses recombinant human P2X7 responses.","date":"2015","source":"Purinergic signalling","url":"https://pubmed.ncbi.nlm.nih.gov/26341077","citation_count":24,"is_preprint":false},{"pmid":"30926287","id":"PMC_30926287","title":"Critical Role of ATP-P2X7 Axis in UV-Induced Melanogenesis.","date":"2019","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/30926287","citation_count":24,"is_preprint":false},{"pmid":"37511507","id":"PMC_37511507","title":"The P2X7 Receptor, a Multifaceted Receptor in Alzheimer's Disease.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37511507","citation_count":23,"is_preprint":false},{"pmid":"33441488","id":"PMC_33441488","title":"P2RX7 at the Host-Pathogen Interface of Infectious Diseases.","date":"2021","source":"Microbiology and molecular biology reviews : MMBR","url":"https://pubmed.ncbi.nlm.nih.gov/33441488","citation_count":23,"is_preprint":false},{"pmid":"36982485","id":"PMC_36982485","title":"The P2X7 Receptor as a Mechanistic Biomarker for Epilepsy.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36982485","citation_count":22,"is_preprint":false},{"pmid":"34281162","id":"PMC_34281162","title":"The P2X7 Receptor: A Promising Pharmacological Target in Diabetic Retinopathy.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34281162","citation_count":22,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45340,"output_tokens":5975,"usd":0.112823,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14523,"output_tokens":5660,"usd":0.107057,"stage2_stop_reason":"end_turn"},"total_usd":0.21988,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"P2X7 receptor C-terminal SH3 death domain interacts with Src tyrosine kinase, and this interaction mediates downstream Pannexin-1 (Panx1) activation. TAT-peptides spanning the P2X7R C-terminus competed with Src binding, reducing Panx1-dependent large-conductance currents and membrane permeabilization to dye. Src tyrosine phosphorylation following BzATP stimulation was blocked by KN-62, TAT-P2X7 peptide, and Src inhibitor PP2.\",\n      \"method\": \"Whole-cell patch-clamp electrophysiology, siRNA knockdown of Panx1, competition assay with membrane-permeant TAT-P2X7 peptides, pharmacological inhibition (KN-62, PP2, carbenoxolone, mefloquine), dye uptake permeabilization assay\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal functional assays (electrophysiology + permeabilization + competition peptide), single lab but multiple orthogonal methods\",\n      \"pmids\": [\"18596211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"P2X7 receptor directly interacts with NLRP3 inflammasome scaffold protein at discrete subplasmalemmal sites. ATP or BzATP stimulation caused localized cytoplasmic Ca2+ increases that drove P2X7R recruitment and a 4-fold increase in P2X7R/NLRP3 co-immunoprecipitation within 1–2 min. P2X7R down-modulation also caused 2–8-fold up-regulation of NLRP3 mRNA in microglial cells and primary macrophages from P2X7R-/- mice.\",\n      \"method\": \"Coimmunoprecipitation, confocal microscopy, RT-PCR, Western blot, calcium imaging, P2X7R-/- primary cells\",\n      \"journal\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP with confocal co-localization, genetic KO validation, multiple orthogonal methods in single study\",\n      \"pmids\": [\"25690658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Paxillin acts as a molecular bridge between P2X7 receptor and NLRP3 inflammasome. Extracellular ATP induces paxillin phosphorylation and promotes formation of a P2X7R-Paxillin-NLRP3 ternary complex at the plasma membrane. Paxillin facilitates NLRP3 deubiquitination via USP13, and paxillin is required for ATP-induced NLRP3 inflammasome activation in mouse BMDMs, BMDCs, and human PBMCs/THP-1 macrophages.\",\n      \"method\": \"Co-immunoprecipitation, confocal microscopy showing membrane translocation, genetic knockdown/knockout, deubiquitination assay, USP13 identification, human primary cell functional assays\",\n      \"journal\": \"BMC biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP of ternary complex, deubiquitination biochemistry, validated in multiple cell types including primary human cells\",\n      \"pmids\": [\"33243234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"P2X7 receptor activation regulates rapid unconventional secretion of transglutaminase-2 (TG2). Extracellular ATP promotes TG2 secretion from macrophages via P2X7R; introduction of functional P2X7R into HEK293 cells is sufficient to confer TG2 export. TG2 release requires receptor membrane pore formation (not Ca2+ signaling alone or membrane depolarization), does not involve pannexin channels, and is pharmacologically separable from microvesicle shedding. A gain-of-function P2X7R mutation associated with autoimmune disease caused enhanced TG2 externalization correlating with increased pore activity.\",\n      \"method\": \"Pharmacological antagonism, heterologous expression in HEK293 cells, gain-of-function mutation analysis, separation of vesicle shedding from secretion by pharmacological agents, pore formation assay\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reconstitution in HEK293 cells, multiple pharmacological dissections, gain-of-function mutation validation, multiple orthogonal readouts\",\n      \"pmids\": [\"26542019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"P2X4 and P2X7 receptor subunits can physically associate to form heterotrimeric channels, detected by FRET between fluorophore-labeled subunits in Xenopus oocytes. However, electrophysiological analysis of ATP-induced whole-cell currents, concentration-response curves, and effects of subtype-specific drugs (ivermectin, PSB-15417, oATP, A438079) were consistent with homomeric P2X4 and P2X7 channels coexisting, with no electrophysiologically distinct heteromeric phenotype.\",\n      \"method\": \"FRET between fluorophore-tagged subunits expressed in Xenopus oocytes, two-electrode voltage clamp electrophysiology, pharmacological dissection with subtype-selective agents\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — FRET physical interaction established, electrophysiology shows no distinct functional heteromer; single lab with two orthogonal methods\",\n      \"pmids\": [\"29213241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"P2X7 receptor localizes to mitochondria in fibroblasts, microglial cells, and heart tissue. Loss of P2X7R decreases basal respiratory rate, ATP-coupled respiration, maximal uncoupled respiration, resting mitochondrial potential, and mitochondrial matrix Ca2+ levels. P2X7R-null mice have larger hearts with smaller mitochondria, reduced stroke volume, ejection fraction, fractional shortening, and cardiac output, and severely reduced physical fitness.\",\n      \"method\": \"Subcellular fractionation and confocal localization to mitochondria, mitochondrial respirometry (Seahorse), mitochondrial Ca2+ measurement, cardiac ultrasound in P2rx7-/- mice, treadmill fitness testing\",\n      \"journal\": \"Function (Oxford, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct fractionation/imaging localization tied to functional consequence in multiple cell types and in vivo cardiac/metabolic phenotype in KO mice\",\n      \"pmids\": [\"35330818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"P2X7 receptor participates in multinucleated giant cell (MGC) formation. Blockade with a specific monoclonal antibody prevents macrophage fusion in vitro. P2X7-high expressing phagocytes fuse only with other P2X7-high cells. During MGC formation, caspase-3 is activated (a P2X7-stimulated enzyme), and P2X7R is preferentially localized at cell-to-cell contact sites.\",\n      \"method\": \"Monoclonal antibody blockade, cell selection for high/low P2X7 expression, caspase-3 activity assay, immunolocalization at cell contacts, ATP-degrading enzyme controls (apyrase/hexokinase)\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody blockade plus cell-selection epistasis plus localization study, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"10982408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"P2X7 receptor expression promotes tumor growth in vivo. HEK293 cells expressing P2X7 showed increased tumorigenicity, proliferation, reduced apoptosis, elevated NFATc1 activation, enhanced vascular network, and elevated VEGF secretion compared to controls. Tumor growth and neoangiogenesis were blocked by intratumoral oxidized-ATP (P2X7 inhibitor), VEGF-blocking antibody bevacizumab, or P2X7 silencing in vivo.\",\n      \"method\": \"In vivo xenograft tumor model, intratumoral inhibitor injection, P2X7 silencing (siRNA in vivo), anti-VEGF antibody treatment, immunohistochemistry, VEGF measurement\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo gain-of-function and loss-of-function (inhibitor + silencing), mechanistic dissection via anti-VEGF intervention, multiple orthogonal readouts\",\n      \"pmids\": [\"22505653\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Tet1 and Tet2 methylcytosine dioxygenases maintain mesenchymal stem cell (MSC) homeostasis via demethylation of the P2rX7 promoter. Tet1/Tet2 double knockout reduces P2rX7 expression, decreasing exosome release and causing intracellular accumulation of miR-297a-5p, miR-297b-5p, and miR-297c-5p, which inhibit Runx2 signaling and impair BMMSC function. Overexpression of P2rX7 in Tet1/2 double KO mice rescues the impaired BMMSCs and osteoporotic phenotype.\",\n      \"method\": \"Genetic knockout (Tet1/Tet2 DKO mice), promoter methylation analysis, exosome quantification, miRNA profiling, Runx2 signaling assay, P2rX7 overexpression rescue experiment\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO phenotype rescued by specific overexpression, epigenetic mechanism (promoter demethylation) linked to downstream miRNA/Runx2 pathway, multiple orthogonal methods\",\n      \"pmids\": [\"29858571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"P2X7 receptor activation induces release of CD14 (a GPI-anchored LPS co-receptor) in extracellular vesicles from macrophages, resulting in net reduction of membrane CD14 and functionally attenuating LPS-induced (but not monophosphoryl lipid A-induced) pro-inflammatory cytokine production. In a murine sepsis model, P2X7 activity maintained elevated circulating CD14 levels; reduced P2X7 activity correlated with higher bacterial load, exacerbated organ damage, and premature death.\",\n      \"method\": \"Extracellular vesicle isolation, flow cytometry for CD14 membrane levels, LPS stimulation assay, P2X7-/- mice in a sepsis model, bacterial load measurement\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic in vitro dissection of vesicle-mediated CD14 shedding with functional consequence, validated in vivo with KO mice in sepsis model\",\n      \"pmids\": [\"33135636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"P2X7 stimulation of tumor-infiltrating effector CD8+ T cells induces cellular senescence via mitochondrial reactive oxygen species generation and p38 MAPK-dependent upregulation of Cdkn1a (p21Waf1/Cip1), impairing cell cycling. Adoptive transfer of P2rx7-/- tumor-specific CD8+ T cells significantly reduced tumor growth and extended survival compared to wild-type T cells in mice.\",\n      \"method\": \"Genetic KO (P2rx7-/-) adoptive T cell transfer, cell cycle analysis, mitochondrial ROS measurement, p38 MAPK inhibition, p21 upregulation assay, in vivo tumor growth measurement\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic KO adoptive transfer with mechanistic dissection of ROS/p38/p21 pathway, multiple orthogonal methods\",\n      \"pmids\": [\"32699136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"P2X7 receptor regulates astroglial autophagy (clasmatodendrosis) after status epilepticus through a MAPK1/2-SP1-HSPB1 signaling axis. Loss of P2rx7 leads to prolonged HSPB1 induction due to impaired MAPK1/2-mediated SP1 phosphorylation; upregulated HSPB1 then triggers ER stress and PRKAA1(AMPK1)/ULK1- and AKT1/GSK3B/SH3GLB1-mediated autophagic pathways independently of mTOR.\",\n      \"method\": \"P2rx7-/- mice, kainic acid-induced status epilepticus model, Western blot for pathway components, phosphorylation analysis of SP1 and MAPK1/2\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined signaling pathway dissection, single lab, in vivo/ex vivo evidence\",\n      \"pmids\": [\"29749377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ATP-P2X7 receptor axis promotes UV-induced melanogenesis. Extracellular ATP released from UVB-irradiated keratinocytes activates P2X7R on melanocytes to promote melanin production via intracellular Ca2+ and PKC/CREB signaling. CRISPR/Cas9 P2X7 knockout melanocytes (MNT1) failed to upregulate MITF when co-cultured with UV-irradiated keratinocytes, confirming P2X7R is required for this paracrine signaling.\",\n      \"method\": \"P2X7R pharmacological blockade, CRISPR/Cas9 knockout of P2X7 in melanocytes, co-culture with UV-irradiated keratinocytes, MITF expression assay, melanin measurement, Ca2+ signaling and PKC/CREB pathway analysis\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR KO with co-culture model plus pharmacological blockade plus downstream signaling mechanistic dissection, multiple orthogonal methods\",\n      \"pmids\": [\"30926287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Irradiation of glioblastoma (GBM) cells causes a dramatic isoform switch: P2X7A splice variant is down-regulated and P2X7B is up-regulated. P2X7B activation by extracellular ATP after irradiation generates a trophic/growth-promoting stimulus, as P2X7 blockers during post-irradiation recovery potentiated irradiation-dependent cytotoxicity.\",\n      \"method\": \"Isoform-specific RT-PCR/Western blot before and after irradiation, P2X7 pharmacological blockade post-irradiation, cell viability assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — isoform expression shift with pharmacological functional follow-up, single lab, two orthogonal methods\",\n      \"pmids\": [\"35075119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"P2X7 receptor deletion in mice suppresses gamma-radiation-induced hyposalivation. Irradiated P2X7R-/- mice maintained normal stimulated salivary flow rates, whereas wild-type irradiated mice showed significant decreases. P2X7R activation elevated PGE2 release from parotid cells following gamma-radiation, and pharmacological P2X7R antagonism (A438079) preserved salivary flow rates in wild-type mice.\",\n      \"method\": \"P2X7R-/- mouse model, gamma-irradiation, stimulated salivary flow rate measurement, PGE2 release assay from primary parotid cells, pharmacological antagonism (A438079), apoptosis assay\",\n      \"journal\": \"American journal of physiology. Regulatory, integrative and comparative physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with pharmacological confirmation and defined PGE2 mechanism, single lab\",\n      \"pmids\": [\"30892913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"microRNA-211-5p targets P2RX7 mRNA; downregulation of miR-211-5p in epilepsy causes P2RX7 upregulation. P2RX7 regulates GPX4/HO-1 by alleviating lipid peroxidation through suppression of MAPK/ERK signaling, contributing to neuronal ferroptosis. Genetic silencing of P2RX7 or induction of miR-211-5p significantly reduced seizure score and duration in murine models.\",\n      \"method\": \"Bioinformatics, epilepsy patient blood samples, mouse epilepsy models (PTZ and KA), miR-211-5p overexpression, P2RX7 genetic silencing, GPX4/HO-1/ERK pathway Western blot, seizure behavioral scoring\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic silencing with defined pathway readouts, confirmed in multiple models, single lab\",\n      \"pmids\": [\"38191407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"P2X7 receptor expression is required for glioma radiosensitivity. P2X7R silencing blocked gamma-radiation (2 Gy)-induced cytotoxicity in glioma cells in a time-dependent pore-activity-dependent manner (measured by ethidium bromide uptake). In vivo, P2X7R-silenced GL261-bearing mice failed to respond to radiotherapy (8 Gy), while wild-type P2X7R-expressing mice showed significant tumor volume reduction. ATP acted synergistically with radiotherapy to increase annexin V incorporation.\",\n      \"method\": \"P2X7R siRNA silencing, pharmacological antagonism, ethidium bromide pore uptake assay, annexin V apoptosis assay, in vivo GL261 tumor model with radiotherapy, tumor volume measurement\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo loss-of-function with defined mechanistic pore-activity readout, single lab\",\n      \"pmids\": [\"26358881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Paroxetine inhibits human P2X7 receptor responses in a concentration-dependent manner (IC50 ~24 µM), reducing ATP-induced dye uptake and inward currents. Trifluoperazine also suppresses human P2X7 responses (IC50 ~6.4 µM). Neither drug inhibited rodent P2X7, and mutation of residue F95L did not alter the inhibitory effect of either drug, indicating they do not bind at this known site. Both drugs suppressed P2X7-induced IL-1β secretion from LPS-primed human CD14+ monocytes.\",\n      \"method\": \"Recombinant human P2X7 in HEK-293 cells, dye uptake assay, whole-cell patch clamp, site-directed mutagenesis (F95L), primary human monocyte IL-1β secretion assay, species comparison (human vs. rodent P2X7)\",\n      \"journal\": \"Purinergic signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro electrophysiology and mutagenesis on recombinant receptor plus primary cell functional assay, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"26341077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"P2X7 receptor activation by P2RX7 stimulation in glioblastoma cells promotes pore formation as measured by ethidium bromide uptake, and this activity is essential for radiation-induced cytotoxicity. Both P2X7A (full-length) and P2X7B (truncated C-terminus) isoforms are expressed in GBM, with distinct contributions to cell survival versus death responses.\",\n      \"method\": \"Isoform-specific expression analysis, ethidium bromide pore uptake assay, pharmacological blockade, irradiation experiments, cell viability\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — isoform-level pharmacological data, single lab, limited mechanistic resolution for isoform-specific function\",\n      \"pmids\": [\"35075119\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"P2X7R is a trimeric, ATP-gated non-selective cation channel whose long intracellular C-terminus orchestrates multiple downstream signaling events: it directly binds NLRP3 inflammasome scaffold protein at subplasmalemmal sites (driving localized Ca2+ increases that amplify their association), recruits paxillin as a molecular bridge to facilitate USP13-mediated NLRP3 deubiquitination and inflammasome activation, and its C-terminal SH3 death domain engages Src kinase to activate Pannexin-1 large-conductance currents; additionally, P2X7R localizes to mitochondria and is required for normal mitochondrial respiration and Ca2+ homeostasis, mediates unconventional TG2 secretion and vesicular CD14 release contingent on macropore formation, promotes tumor growth via NFATc1/VEGF signaling, and drives macrophage multinucleated giant cell formation through caspase-3 activation at cell-contact sites, with its expression regulated epigenetically via Tet1/Tet2-dependent demethylation of the P2rX7 promoter and post-transcriptionally by miR-211-5p.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"P2RX7 (P2X7R) is an ATP-gated cation channel whose activation couples extracellular nucleotide sensing to membrane permeabilization and a broad program of inflammatory, metabolic, and proliferative signaling [#1, #3]. Its cytoplasmic C-terminus serves as a signaling hub: an SH3 death domain engages Src kinase to drive Pannexin-1 large-conductance currents and dye-permeable membrane permeabilization [#0], and upon ATP/BzATP stimulation the receptor is recruited to subplasmalemmal sites where localized Ca2+ rises promote its direct association with the NLRP3 inflammasome scaffold [#1]. Paxillin bridges P2X7R and NLRP3 into a ternary complex and enables USP13-mediated NLRP3 deubiquitination, a step required for ATP-induced inflammasome activation in macrophages, dendritic cells, and human monocytes [#2]. Through macropore formation the receptor drives unconventional secretion of transglutaminase-2 and vesicular shedding of CD14, the latter dampening LPS responsiveness and limiting bacterial burden in sepsis [#3, #9]. P2X7R also localizes to mitochondria and is required for normal respiration, mitochondrial Ca2+ loading, and cardiac/physical fitness in vivo [#5]. In the tumor context it promotes tumor growth via NFATc1-dependent VEGF secretion and neoangiogenesis [#7], yet in tumor-infiltrating CD8+ T cells it imposes mitochondrial-ROS/p38/p21-dependent senescence that restrains anti-tumor immunity [#10]. Receptor abundance is set epigenetically by Tet1/Tet2-dependent demethylation of the P2rX7 promoter, which controls exosome release and Runx2 signaling in mesenchymal stem cells [#8], and post-transcriptionally by miR-211-5p [#15]. P2X7R further mediates paracrine UV-induced melanogenesis [#12], macrophage multinucleated giant cell formation [#6], and modulates seizure, autophagy, and radiation-response phenotypes across neural and tumor tissues [#11, #15, #16].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established that P2X7R is not merely a channel but a driver of macrophage fusion, linking receptor activity to multinucleated giant cell formation and a cell-death effector.\",\n      \"evidence\": \"Monoclonal antibody blockade, P2X7-high/low cell selection, caspase-3 activity assay, and immunolocalization at cell contacts\",\n      \"pmids\": [\"10982408\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular fusion machinery downstream of P2X7R not identified\", \"Direct caspase-3 substrate at contact sites unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined how the P2X7R C-terminus transduces signal beyond ion flux, showing its SH3 death domain recruits Src to activate Pannexin-1 and membrane permeabilization.\",\n      \"evidence\": \"Whole-cell patch-clamp, Panx1 siRNA, competing TAT-P2X7 C-terminal peptides, and pharmacological inhibition in a dye-uptake assay\",\n      \"pmids\": [\"18596211\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct structural basis of SH3-Src binding not resolved\", \"Whether Src acts directly on Panx1 not established\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed P2X7R expression is sufficient to promote tumor growth, connecting receptor activity to NFATc1-driven VEGF secretion and neoangiogenesis.\",\n      \"evidence\": \"HEK293 xenografts with in vivo P2X7 silencing, oxidized-ATP and anti-VEGF (bevacizumab) intervention, immunohistochemistry\",\n      \"pmids\": [\"22505653\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Link from P2X7R activation to NFATc1 activation not biochemically mapped\", \"Endogenous tumor relevance vs. HEK overexpression\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified the direct physical interaction between P2X7R and the NLRP3 scaffold, providing a spatial mechanism (subplasmalemmal Ca2+) for inflammasome assembly.\",\n      \"evidence\": \"Reciprocal Co-IP, confocal co-localization, calcium imaging, and P2X7R-/- primary cells with NLRP3 mRNA quantification\",\n      \"pmids\": [\"25690658\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interaction interface residues not mapped\", \"Mechanism of Ca2+-driven recruitment unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated that P2X7R macropore formation, not Ca2+ or depolarization alone, drives unconventional TG2 secretion, dissecting pore activity from other receptor outputs.\",\n      \"evidence\": \"Heterologous HEK293 reconstitution, pharmacological dissection separating secretion from vesicle shedding, gain-of-function disease-mutant analysis\",\n      \"pmids\": [\"26542019\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular identity of the secretory route downstream of pore formation unknown\", \"How TG2 accesses the pore not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Tested whether P2X4 and P2X7 form functional heteromers, finding physical association by FRET but no electrophysiologically distinct heteromeric channel.\",\n      \"evidence\": \"FRET between tagged subunits in Xenopus oocytes and two-electrode voltage clamp with subtype-selective pharmacology\",\n      \"pmids\": [\"29213241\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological significance of P2X4-P2X7 association unclear\", \"Heteromer behavior in native cells untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Revealed epigenetic control of P2rX7 abundance, placing the receptor downstream of Tet1/Tet2 demethylation in mesenchymal stem cell and bone homeostasis.\",\n      \"evidence\": \"Tet1/Tet2 DKO mice, promoter methylation analysis, exosome/miRNA profiling, and P2rX7 overexpression rescue of osteoporotic phenotype\",\n      \"pmids\": [\"29858571\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How P2X7R activity controls exosome release mechanistically unclear\", \"Direct miR-297/Runx2 link to receptor pore vs. signaling untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Connected P2X7R to innate immune tuning by showing it sheds membrane CD14 in vesicles to attenuate LPS responses and limit bacterial load in sepsis.\",\n      \"evidence\": \"EV isolation, flow cytometry of membrane CD14, LPS stimulation, and P2X7-/- mouse sepsis model with bacterial load measurement\",\n      \"pmids\": [\"33135636\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism coupling pore formation to CD14 vesicle loading not defined\", \"Whether shedding is direct or via downstream proteases unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked P2X7R loss to dysregulated astroglial autophagy, defining a MAPK1/2-SP1-HSPB1 signaling axis after status epilepticus.\",\n      \"evidence\": \"P2rx7-/- mice in kainic acid model with phosphorylation analysis of SP1 and MAPK1/2 and autophagy pathway Western blots\",\n      \"pmids\": [\"29749377\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct receptor-to-MAPK1/2 coupling not established\", \"Single-lab in vivo correlative pathway data\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed P2X7R mediates a paracrine keratinocyte-melanocyte signaling loop driving UV-induced melanogenesis via Ca2+/PKC/CREB and MITF.\",\n      \"evidence\": \"CRISPR/Cas9 P2X7 knockout melanocytes co-cultured with UV-irradiated keratinocytes, pharmacological blockade, MITF and melanin assays\",\n      \"pmids\": [\"30926287\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct CREB target genes downstream not mapped\", \"Relevance to human pigmentation in vivo untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined paxillin as the molecular bridge linking P2X7R to NLRP3, with USP13-mediated deubiquitination as a required activation step.\",\n      \"evidence\": \"Co-IP of P2X7R-Paxillin-NLRP3 ternary complex, deubiquitination assay identifying USP13, and functional validation in mouse and human primary cells\",\n      \"pmids\": [\"33243234\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ATP triggers paxillin phosphorylation upstream unclear\", \"Stoichiometry/order of ternary complex assembly unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Uncovered an immunosuppressive cell-intrinsic role: P2X7R drives senescence in tumor-infiltrating CD8+ T cells, identifying a target to enhance anti-tumor immunity.\",\n      \"evidence\": \"P2rx7-/- adoptive T cell transfer, mitochondrial ROS measurement, p38 MAPK inhibition, p21 upregulation, and in vivo tumor growth\",\n      \"pmids\": [\"32699136\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How receptor signaling generates mitochondrial ROS not resolved\", \"Whether senescence is reversible by transient blockade untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established a non-canonical mitochondrial localization for P2X7R essential for respiration, mitochondrial Ca2+, and organismal cardiac and physical fitness.\",\n      \"evidence\": \"Subcellular fractionation/confocal localization, Seahorse respirometry, mitochondrial Ca2+ measurement, and cardiac ultrasound plus fitness testing in P2rx7-/- mice\",\n      \"pmids\": [\"35330818\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How P2X7R traffics to and functions within mitochondria unknown\", \"Whether mitochondrial pool is channel-active not established\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed P2X7R isoform balance shapes tumor radiation response, with irradiation switching from P2X7A to a growth-promoting P2X7B variant in glioblastoma.\",\n      \"evidence\": \"Isoform-specific RT-PCR/Western blot before and after irradiation with P2X7 blockade and viability assays\",\n      \"pmids\": [\"35075119\", \"35075119\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of the trophic P2X7B signal not defined\", \"Low-resolution dissection of isoform-specific function\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated pore-activity-dependent P2X7R function is required for glioma radiosensitivity in vitro and in vivo, framing the receptor as a radiotherapy modifier.\",\n      \"evidence\": \"P2X7R siRNA silencing, ethidium bromide pore uptake, annexin V apoptosis, and in vivo GL261 radiotherapy model\",\n      \"pmids\": [\"26358881\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How pore activity links to radiation-induced death pathway unclear\", \"Single-lab in vivo data\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed P2X7R activation drives radiation-induced hyposalivation through PGE2 release, identifying a tissue-protection rationale for antagonism.\",\n      \"evidence\": \"P2X7R-/- mice, gamma-irradiation, salivary flow measurement, PGE2 assay from primary parotid cells, and A438079 antagonism\",\n      \"pmids\": [\"30892913\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Coupling of receptor activation to PGE2 synthesis not mapped\", \"Cell type responsible within gland unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Placed P2RX7 within a miR-211-5p-controlled circuit that drives neuronal ferroptosis via GPX4/HO-1 and MAPK/ERK in epilepsy.\",\n      \"evidence\": \"Patient blood samples, PTZ and KA mouse models, miR-211-5p overexpression, P2RX7 silencing, GPX4/HO-1/ERK Western blots, and seizure scoring\",\n      \"pmids\": [\"38191407\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct miR-211-5p binding to P2RX7 transcript needs confirmation\", \"How receptor activity modulates ERK/GPX4 mechanistically unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Characterized species-specific pharmacological inhibitors of human P2X7R acting outside the known F95 site, with functional suppression of IL-1beta secretion.\",\n      \"evidence\": \"Recombinant human P2X7 in HEK-293, dye uptake, patch clamp, F95L mutagenesis, species comparison, and primary monocyte IL-1beta assay\",\n      \"pmids\": [\"26341077\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Actual binding site of paroxetine/trifluoperazine not identified\", \"Whether inhibition is allosteric or competitive unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how a single receptor coordinates its distinct outputs (channel, macropore, mitochondrial, scaffolding) at the structural and trafficking level, and whether these are spatially segregated receptor pools or sequential conformational states.\",\n      \"evidence\": \"No timeline discovery resolves the structural switch governing channel vs. macropore vs. mitochondrial functions.\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model connecting pore dilation to scaffolding functions\", \"Mechanism of mitochondrial targeting unknown\", \"Determinants of context-specific signaling output undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005216\", \"supporting_discovery_ids\": [1, 3]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 12]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [3, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 2, 3]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 2, 9]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 12]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [10, 15, 16]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"complexes\": [\n      \"P2X7R-Paxillin-NLRP3 ternary complex\",\n      \"P2X4-P2X7 heterotrimer\"\n    ],\n    \"partners\": [\n      \"NLRP3\",\n      \"PXN\",\n      \"USP13\",\n      \"SRC\",\n      \"PANX1\",\n      \"P2RX4\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}